Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

completed350%
terminated233%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03005327
completedphase_1

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

NCT02667886
terminatedphase_1

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

NCT02923531
unknownphase_1

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

NCT05103917
completedphase_1

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

NCT02823405
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03005327Phase 2

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Completed
NCT02667886Phase 1

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Completed
NCT02923531Phase 1

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Terminated
NCT05103917Phase 1

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Unknown
NCT02823405Phase 1

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Completed
NCT02680782Phase 1

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6